Anixa Biosciences
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3150 Almaden Expy Ste 250, San Jose, Cal...Phone Number
(408) 708-9808Website
www.anixa.comRevenue
<$5 MillionStock Symbol
ANIXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Anixa Biosciences
Anixa Biosciences is a clinical stage biotechnology company focused on the treatment and prevention of cancer.Explore more
Anixa Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anixa Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Anixa Biosciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Anixa Biosciences launches new products
Funding: Get notified immidiatlly once Anixa Biosciences has new funding data
Anixa Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Anixa Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Anixa Biosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Anixa Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Anixa Biosciences
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Anixa Biosciences
Compare insights from companies similar to Anixa Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Anixa Biosciences
<$5M
1-10
Public
-
1982
MC
Michael CatelaniPresident & Chief Operating Officer & Chief Financial Officer
Company Profile Activity
Activity Insights
Anixa Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Anixa Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Anixa Biosciences.
Anixa Biosciences Tech Stack
A closer look at the technologies used by Anixa Biosciences
See more technologies
Most Recent Scoops
Partnership
Partnership, Research & Development, Medical Research, Pharmaceuticals
Partnership
Project
Partnership, Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Anixa Biosciences is planning a Phase 2 trial for its breast cancer vaccine, initially considering an all-comers approach. The company believes alpha-lactalbumin is expressed in multiple forms of breast cancer, with the bulk of their research focused on triple-negative breast cancer.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Anixa Biosciences has announced two immunotherapy programs currently in Phase 1 clinical trials: an ovarian cancer CAR-T program and a breast cancer vaccine. The company reports encouraging data from both trials.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Medical Research, Pharmaceuticals
Anixa Biosciences News & Media
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc....Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater...Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, lira-cel, presentation highlights positive survival observations from ongoing Phase 1...Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74%...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anixa Biosciences
Sign Up For FreeTo access detailed company insights
Anixa Biosciences is a clinical stage biotechnology company focused on the treatment and prevention of cancer.... Read More
